已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Subcutaneous Infliximab, CT-P13 SC: A Profile of Its Use in the EU

医学 英夫利昔单抗 生物仿制药 溃疡性结肠炎 银屑病性关节炎 强直性脊柱炎 类风湿性关节炎 银屑病 炎症性肠病 内科学 疾病 皮肤病科 胃肠病学
作者
Matt Shirley
出处
期刊:Clinical Drug Investigation [Adis, Springer Healthcare]
卷期号:41 (12): 1099-1107 被引量:4
标识
DOI:10.1007/s40261-021-01093-8
摘要

CT-P13 (Remsima®; Inflectra®), a biosimilar of reference infliximab (Remicade®), provides a useful alternative for patients requiring infliximab therapy and, as with other biosimilar agents, has the potential to reduce treatment costs. Furthermore, the availability of CT-P13 in a subcutaneous formulation (CT-P13 SC), with the possibility (after adequate training) of self-administration at home, has the potential to both improve patient convenience and reduce the burden on the healthcare system. The initial approval of CT-P13 SC, for use in the treatment of rheumatoid arthritis in adults, was based on the findings of a randomised, double-blind phase I/III trial which demonstrated the non-inferiority of CT-P13 SC administered once every 2 weeks to intravenous CT-P13 (CT-P13 IV) administered once every 8 weeks in reducing disease activity in patients with active rheumatoid arthritis. Subsequently, based on pharmacokinetic data in patients with inflammatory bowel disease, CT-P13 SC has also been approved in the EU for use in the treatment of Crohn's disease, ulcerative colitis and, by extrapolation, ankylosing spondylitis, psoriatic arthritis and psoriasis, in adults.Biosimilars are biological medical agents that are designed to closely replicate a reference medicine while potentially reducing treatment costs. CT-P13 (Remsima®; Inflectra®) in the intravenous formulation (CT-P13 IV) is a biosimilar of reference infliximab (Remicade®) and is approved in the EU for use in the treatment of rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriatic arthritis and psoriasis in adults and Crohn’s disease and ulcerative colitis in children aged ≥ 6 years. Unlike reference infliximab, CT-P13 is now also available in a formulation that can be administered by subcutaneous injection (CT-P13 SC). CT-P13 SC is approved for use in adults (only) in all indications as for CT-P13 IV, with approval based on clinical trials which showed that the subcutaneous formulation has non-inferior efficacy to CT-P13 IV in the treatment of rheumatoid arthritis and has non-inferior pharmacokinetics to the intravenous formulation in patients with inflammatory bowel disease. In conclusion, CT-P13 SC provides a useful alternative for adult patients requiring infliximab therapy and, with the possibility of self-administration at home, has the potential both to improve patient convenience and to reduce the burden on the healthcare system.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
G1997完成签到,获得积分10
1秒前
Ztx完成签到,获得积分10
4秒前
daydayup完成签到 ,获得积分10
4秒前
一直向前发布了新的文献求助10
5秒前
Akim应助Sienna采纳,获得10
5秒前
7秒前
9秒前
淡然绝山完成签到,获得积分10
9秒前
ding应助mjsdx采纳,获得10
10秒前
阿梅梅梅发布了新的文献求助10
11秒前
Lyl完成签到 ,获得积分10
14秒前
福福完成签到,获得积分10
14秒前
好呀好呀发布了新的文献求助10
14秒前
16秒前
24秒前
CC完成签到,获得积分10
25秒前
dd完成签到 ,获得积分10
26秒前
wf完成签到,获得积分10
27秒前
单身的青柏完成签到 ,获得积分10
27秒前
科研达人发布了新的文献求助10
28秒前
甜甜的以筠完成签到 ,获得积分10
28秒前
小熊完成签到,获得积分10
29秒前
shentaii完成签到,获得积分10
30秒前
32秒前
ddk完成签到 ,获得积分10
32秒前
呼啦呼啦完成签到 ,获得积分10
33秒前
会科研的胡萝卜完成签到,获得积分10
34秒前
兰月满楼完成签到 ,获得积分10
34秒前
点墨完成签到 ,获得积分10
34秒前
lizibelle完成签到,获得积分20
35秒前
li完成签到 ,获得积分10
39秒前
孤独蘑菇完成签到 ,获得积分10
39秒前
39秒前
Hello应助max采纳,获得10
41秒前
HMG1COA完成签到 ,获得积分10
42秒前
善学以致用应助Nayvue采纳,获得10
44秒前
XXGG完成签到 ,获得积分10
44秒前
所所应助包容的奇异果采纳,获得10
45秒前
taku完成签到 ,获得积分10
46秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
Aktuelle Entwicklungen in der linguistischen Forschung 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989957
求助须知:如何正确求助?哪些是违规求助? 3532034
关于积分的说明 11256000
捐赠科研通 3270880
什么是DOI,文献DOI怎么找? 1805070
邀请新用户注册赠送积分活动 882252
科研通“疑难数据库(出版商)”最低求助积分说明 809216